460
Views
16
CrossRef citations to date
0
Altmetric
Case Reports

Seizures associated with ertapenem use in patients with CNS disorders and renal insufficiency

&
Pages 983-985 | Received 28 Jul 2008, Published online: 08 Jul 2009

References

  • Teppler H, Gesser RM, Friedland IR, Woods GL, Meibohm A, Herman G, et al. Safety and tolerability of ertapenem. J Antimicrob Chemother 2004; 53(Suppl S2)85–95
  • Sharma A, Raina V. Generalized seizure following ondansetron. Ann Oncol 2001; 12: 131–2
  • von Einsiedel RW, Roesch-Ely D, Diebold K, Sartor K, Mundt C, Bergemann N. H(2)-histamine antagonist (famotidine) induced adverse CNS reactions with long-standing secondary mania and epileptic seizures. Pharmacopsychiatry 2002; 35: 152–4
  • Beloosesky Y, Grosman B, Marmelstein V, Grinblat J. Convulsions induced by metronidazole treatment for Clostridium difficile associated disease in chronic renal failure. Am J Med Sci 2000; 319: 338–9
  • Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–45
  • Norrby SR, Gildon KM. Safety profile of meropenem: a review of nearly 5000 patients treated with meropenem. Scand J Infect Dis 1999; 31: 3–10
  • Norrby SR. Neurotoxicity of carbapenem antibiotics: consequences for their use in bacterial meningitis. J Antimicrob Chemother 2000; 45: 5–7
  • Seto AH, Song JC, Guest SS. Ertapenem associated seizures in a peritoneal dialysis patient. Ann Pharmacother 2005; 39: 352–6
  • Saidel-Odes L, Borer A, Riesenberg K, Smolyakov R, Schlaeffer F. History of cerebrovascular events: a relative contraindication to ertapenem therapy. Clin Infect Dis 2006; 43: 262–3
  • Ong C, Chua AC, Tambyah PA, Fei YS. Seizures associated with ertapenem. Int J Antimicrob Agents 2008; 31: 290
  • Lunde JL, Nelson RE, Storandt HF. Acute seizures in a patient receiving divalproex sodium after starting ertapenem therapy. Pharmacotherapy 2007; 27: 1202–5
  • Livermore DM, Oakton KJ, Carter MW, Warner M. Activity of ertapenem (MK-0826) versus enterobacteriaceae with potent β-lactamases. Antimicrob Agents Chemother 2001; 45: 2831–7
  • Brink AJ, Feldman C, Grolman DC, Muckart D, Pretorius J, Richards GA, et al. Appropriate use of the carbapenems. S Afr Med J 2004; 94: 857–61
  • De Sarro A, Ammendola D, Zappala M, Grasso S, De Sarro GB. Relationship between structure and convulsant properties of some β-lactam antibiotics following intrecerebroventricular microinjection in rats. Antimicrob Agents Chemother 1995; 39: 232–7
  • Day IP, Goudie J, Nishiki K, Williams PD. Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem. Toxicol Lett 1995; 76: 239–43
  • Mistry GC, Majumdar AK, Swan S, Sica D, Fihser A, Xu Y, et al. Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on haemodialysis. J Clin Pharmacol 2006; 46: 1128–38

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.